- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07251998
Effektivitet og sikkerhed af ICP-332 versus placebo hos deltagere med moderat til svær plaque psoriasis
En randomiseret, dobbeltblind, placebokontrolleret, parallelgruppefase 2 klinisk undersøgelse til evaluering af effekt, sikkerhed, farmakokinetik og farmakodynamik af ICP-332 hos patienter med moderat til svær plaque psoriasis
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Anhui
-
Wuhu, Anhui, Kina, 241001
- The Second Affiliated Hospital of Wannan Medical College
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100005
- Beijing Tongren Hospital, Affiliated to Capital Medical University
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina, 400011
- Chongqing Traditional Chinese Medicine Hospital
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350005
- Fujian Medical University First Affiliated Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510091
- Dermatology Hospital of Southern Medical University
-
Shenzhen, Guangdong, Kina, 518020
- Shenzhen People's Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, Kina, 230601
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Luoyang, Henan, Kina, 450000
- The Second Affiliated Hospital of Henan University of Science and Technology
-
Zhengzhou, Henan, Kina, 471000
- Henan Provincial People's Hospital
-
-
Hubei
-
Jingzhou, Hubei, Kina, 434020
- Jingzhou Central Hospital
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Xiangya Hospital of Central South University
-
-
Jiangsu
-
Suzhou, Jiangsu, Kina, 215002
- Suzhou Municipal Hospital
-
Zhenjiang, Jiangsu, Kina, 212001
- Affiliated Hospital of Jiangsu University
-
-
Shandong
-
Jinan, Shandong, Kina, 250012
- Qilu Hospital of Shandong University
-
Jinan, Shandong, Kina, 250022
- Shandong Provincial Hospital of Dermatology
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200040
- Huashan Hospital Affiliated to Fudan University
-
Shanghai, Shanghai Municipality, Kina, 200443
- Shanghai Dermatology Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610000
- Chengdu Second People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300120
- Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
-
-
Yunnan
-
Kunming, Yunnan, Kina, 650000
- The First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310006
- Hangzhou First People's Hospital
-
Hangzhou, Zhejiang, Kina, 310009
- Hangzhou Third People's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).
-
Male or female subjects aged ≥ 18 years and ≤ 70 years
-
A history of plaque psoriasis for ≥6 months at baseline
-
Meet the following three criteria:
- Psoriasis Area and Severity Index (PASI) score ≥12
- Static Physician's Global Assessment (sPGA) score ≥3
- Psoriasis affected Body Surface Area (BSA) ≥10%
-
The subject requires systemic treatment and/or phototherapy.
Exclusion Criteria:
- Diagnosed with non-plaque psoriasis.
- Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
- Presence of clinically serious, progressive, or uncontrolled disease.
- Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
- Pregnant or lactating women.
- The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ICP-332 Dosis A
|
ICP-332 will be administered as tablet for 12 weeks |
|
Eksperimentel: ICP-332 Dosis B
|
ICP-332 will be administered as tablet for 12 weeks |
|
Eksperimentel: ICP-332 Dosis C
|
ICP-332 will be administered as tablet for 12 weeks |
|
Placebo komparator: ICP-332 Placebo
|
Placebo will be administered as tablet for 12 weeks |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentdelen af deltagere med moderat til svær psoriasis, der oplever en 75 % forbedring (reduktion fra baseline) i PASI-score (PASI-75 responsrate) ved uge 12
Tidsramme: Dag 1 til Dag 85
|
Dag 1 til Dag 85
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentage of Participants With PASI-50, PASI-75, PASI-90, PASI-100 on scheduled Visit(except W12 PASI 75)
Tidsramme: Day 1 to Day 85
|
Day 1 to Day 85
|
|
Percentage of Participants at Week12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)
Tidsramme: Day 1 to Day 85
|
Day 1 to Day 85
|
|
Number of Participants With Adverse Events
Tidsramme: Day 1 to Day 113
|
Day 1 to Day 113
|
|
The peak concentration (Cmax)
Tidsramme: Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The time to peak (Tmax)
Tidsramme: Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The half-life (t1/2)
Tidsramme: Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
|
The area under the blood concentration-time curve (AUC0-∞ and AUC0-t)
Tidsramme: Day 1, Day15, Day 29, Day 57
|
Day 1, Day15, Day 29, Day 57
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Yuling Shi, Shanghai Dermatology Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- ICP-CL-00603
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .